VIR

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 17.67 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vir Biotechnology Inc revenue for the last quarter amounts to 240.00K USD, decreased -89.92 % YoY.

Vir Biotechnology Inc. EPS for the last quarter amounts to -1.17 USD, decreased -25.00 % YoY.

Vir Biotechnology Inc (VIR) has 408 emplpoyees as of December 15 2025.

Today VIR has the market capitalization of 930.75M USD.